Zacks Investment Research on MSN2d
AXSM Settles Sunosi Patent Litigation With Hikma PharmaceuticalsAxsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to ...
Zacks Investment Research on MSN4d
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug FilingAxsome Therapeutics AXSM announced that it has received formal feedback from the FDA on its plans to seek approval for AXS-05 ...
In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price ...
2d
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has earned a consensus rating of “Buy” from the fifteen ratings ...
Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Hikma Pharmaceuticals (HKMPF), resolving patent ...
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective hoisted by stock analysts at Robert W. Baird from ...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback